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Abstract
Introduction The introduction of targeted drugs has had a
significant impact on the approach to assessing tumour re-
sponse. These drugs often induce a rapid cytostatic effect
associated with a less pronounced and slower tumoural vol-
ume reduction, thereby impairing the correlation between
the absence of tumour shrinkage and the patient’s unlikeli-
hood of benefit. The aim of the study was to assess the
predictive value of early metabolic response (mR) evaluation
after one cycle, and its interlesional heterogeneity to a later
metabolic and morphological response assessment per
formed after three cycles in metastatic colorectal cancer
(mCRC) patients treated with combined sorafenib and
capecitabine.
Methods This substudy was performed within the framework
of a wider prospective multicenter study on the predictive
value of early FDG PET-CT response assessment (SoMore
study). A lesion-based response analysis was performed, in-
cluding all measurable lesions identified on the baseline PET.
On a per-patient basis, a descriptive 4-class response catego-
rization was applied based upon the presence and proportion
of non-responding lesions. For dichotomic response compar-
ison, all patients with at least one resistant lesion were clas-
sified as non-responding.
Results On baseline FDG PET-CT, 124 measurable “target”
lesions were identified in 38 patients. Early mR assessments
showed 18 patients (47 %) without treatment resistant lesions
and 12 patients (32 %) with interlesional response heteroge-
neity. The NPVand PPVof early mR were 85 % (35/41) and
84% (70/83), respectively, on a per-lesion basis and 95% (19/
20) and 72 % (13/18), respectively, on a dichotomized per-
patient basis.
Conclusions Early mR assessment performed after one cycle
of sorafenib-capecitabine in mCRC is highly predictive of
non-response at a standard response assessment time. The
high NPV (95 %) of early mR could be useful as the basis
for early treatment discontinuation or adaptation to spare pa-
tients from exposure to non-effective drugs.
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Introduction
Colorectal cancer is the third leading cause of cancer death in
the world and continues to be a major health problem world-
wide [1]. Despite improvements in chemotherapy, patients with
metastatic colorectal cancer (mCRC) carry a bleak prognosis
with less than 10 % survivors at 5 years [1]. Recent improve-
ments have been made thanks to the development of a new
generation of oral multikinases inhibitors interfering with cel-
lular proliferation, tumour growth, and angiogenesis [2]. Most
of these drugs are only effective in a limited number of patients
and are associated with significant drug-relatedmorbidity and a
high economic impact for the society [3, 4]. Therefore, it be-
comes essential to improve the cost-effectiveness of these new
drug regimens through the development of predictive bio-
markers designed for a rapid identification of non-responding
patients.
These new medications induce a rare and slow tumoural
shrinkage. Standard RECIST criteria-based morphological re-
sponse assessment is often limited by its low sensitivity for
detecting objective response [5]. Early data indicate that a
sensitive response detection using FDG PET-CT performed
as soon as after one cycle of treatment is possible, and is
correlated with treatment outcome, mostly due to the early
identification of non-responding patients [6–10]. This justifies
studies about the use of FDG PET-CT for metabolic response
(mR) assessment [4, 11–14].
An imaging biomarker for early non-response detection
should have a high negative predictive value to avoid unjustified
early discontinuation of an effective treatment. False-negative
early responses should be avoided through the use of a low
response cut-off, with a decrease of FDG uptake (expressed as
SUVmax) of less than 15 % compared to baseline [15].
Highlighting the interlesional heterogeneity of mR at an
early time point during treatment could be of utmost impor-
tance for the prediction of a patient’s outcome and for clinical
management. Rapid identification and localization of resistant
lesion(s) could be the basis for a more individualized treat-
ment approach.
The objective of this substudy was to assess the evolution
of metabolic resistance over time during therapy.
Materials and methods
Study design
This substudy was performed within the framework of a wider
prospective phase II multicenter study on the predictive value of
FDG PET-CT response assessment for patient outcome predic-
tions in patients with mCRC treated with a combination of so-
rafenib and capecitabine (EudraCT number: 2010-023695-91;
SoMore study clinical trials NCT01290926) [14, 16].
This substudy was conducted at four PET-CT centers, in
collaboration with six clinical participating institutions, in
which patients underwent an early PET at week 3 and an
additional “late PET” at week 6–8 (range: 38–62 days) togeth-
er with the standard RECIST-based morphological response
assessment.
A diagram of the study design is shown in Fig. 1.
The early PET assessment was blinded to the referring on-
cologists, and did not interfere with treatment decisions. This
substudy was approved by the Jules Bordet Institute Ethics
Committee (CE2176) and Ethics Committees of all other par-
ticipating centers.
Patients
From the total cohort of 97 patients included in the SoMore
trial, 41 patients were prospectively enrolled in this substudy.
The patients’ characteristics are shown in Table 1. Enrollment
Fig. 1 Illustration of the study
design. D-7 - D0: day −7 until day
0; W3: week 3; W6-8: weeks 6–8
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criteria were: age>18; Eastern Cooperative Oncology Group
(ECOG) performance status≤1; life expectancy>12 weeks;
at least one RECIST evaluable lesion; ability to undergo the
therapy, and signed informed consent [17]. Patients received
600 mg of sorafenib with escalation to 800 mg, if well toler-
ated. The study dose of capecitabine was 850 mg/m2 twice
daily for 14 days, followed by a 7-day rest period. Changes in
therapy other than dose adaptation for toxicity were not
allowed. Treatment stopping rules were defined according to
either excessive toxicity or clinical or radiological
progression.
FDG PET-CT procedures
All patients were studied using a dedicated FDG PET-CTcam-
era of the locally available brand. Most of the FDG PET-CT
images (92 %) were acquired at the Jules Bordet Institute using
a General Electric (GE) Discovery 690 time of flight (TOF)
PET system, 60 min after injection (range: 60–70 min and did
not differ by more than 15 min from the uptake time for the
baseline FDG PET-CT) of 3.7–4 MBq/kg. All PET scans were
acquired in three-dimensional mode with an acquisition time of
90 s per bed position with an overlap of 23.4 %. PET images
were reconstructed with the built-in GE VUE Point Fx algo-
rithm, an ordered subset expectation maximization algorithm
with two iterations and 18 subsets, and were postfiltered with a
6.4-mm full-width at half-maximum (FWHM) Gaussian func-
tion. The images were corrected for attenuation and for scatter
using the CT data. CT was performed with 64 slices helical
scanner (VCT; GE Medical Systems). The tension was
120 kV, and the current was modulated by the Auto-mA soft-
ware with a noise index of 30 (range: 30–200mA) and ASIR®.
The other CTacquisition parameters were 0.5 s per CT rotation
and a pitch of 0.98. The CT images were reconstructed with the
ASIR algorithm set at 40 %, with a matrix of 512 × 512
(0.97×0.97 mm pixel size) and a slice thickness of 2.5mm.
The PETmatrix was 192×192 pixels of 2.73×2.73 mmwith a
slice thickness of 3.27 mm.
For three patients, FDG PET-CT images were acquired
using a Philips Gemini 16P (for one patient), a Philips
Gemini TOF 16 (for one patient), and a GE Discovery LS
system (for one patient). Patient preparation (>6 h fasting,
blood glucose levels less than 150 mg/dL before FDG injec-
tion), imaging, and reconstruction protocols were kept con-
stant for all FDG PET-CT performed in the four standardized
PET-CT centers.
The time interval between tracer injection and start of the
PET-CT acquisition at early and late time points did not differ
by more than 15 min from the interval recorded at baseline.
The difference of net injected activity between the baseline
and the two subsequent scans did not exceed 20 %, except
for one patient (difference of −47 % compared to baseline).
FDG PET-CT analysis
All FDG PET-CT images were independently reviewed by
two experienced nuclear medicine physicians not involved
in treating the patients and blinded to both medical records
and treatment outcomes on a dedicated workstation
(Advantage Workstation; GE Healthcare) using the commer-
cial PET VCAR software 4.6. The mR assessment process
comprised four phases: identifying the measurable (target)
lesions on the baseline FDG PET-CT; assessing the mR of
each target lesion (lesion-based mR); categorizing the mR
distribution into four classes; and dichotomizing the overall
mR (patient-based mR).
Both reviews were compared. In all cases of mR classifi-
cation discrepancy, a final unanimous consensus was
achieved.
Criteria for identification of target lesions: The criteria
were adapted from PERCIST [18]. At baseline, FDG PET-
CT target lesions were defined as follows: lesion size
>15 mm in transversal diameter on a registered CT image,
and a marked accumulation of FDG with SUV normalized
to lean body mass higher than 1.5 x mean liver SUV+2 x
SD of mean liver SUVor, in the presence of liver metastasis,
2.0 x mean aorta SUV+3 x SD of mean aorta SUV. Normal
background FDG uptake was determined by drawing a refer-
ence area as a 3 cm diameter spherical region of interest (ROI)
in the right lobe of the liver. In patients with liver metastases,
the reference area was drawn as a 2 cm diameter spherical ROI





Mean ± SD 62± 10
Median (min-max) 64 (41 – 76)
Gender
Men 22 58 %
Women 16 42 %
ECOG Performance Status
0 23 61 %
1 15 39 %
Previous use of Bevacizumab
No 20 53 %
Yes 18 47 %
Number of previous chemotherapy lines
2 18 47 %
3 12 32 %
4 3 8 %
5 2 5 %
6 3 8 %
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in the descending thoracic aorta. The maximal number of tar-
get lesions was non-restricted.
Lesion-based mR assessment: This assessment was per-
formed on both early and late PET-CTs, and the defined re-
sponse to therapy for each target lesion was expressed as a
continuous variable representing the percentage change in
SUVmax between the baseline PET and early/late PET accord-
ing to the following formula: delta SUVmax= (SUVmax re-
sponse – SUVmax baseline)/SUVmax baseline. Early mR were
classified by applying a response threshold of a 15% decrease
of SUVmax. Such a low cut-off was chosen to obtain the
highest negative predictive value for response, as calculated
by Buvat et al. [15]. Late mR performed after three cycles was
defined using the EORTC criteria for PET-response assess-
ment and had a cut-off value of a 25 % decrease [19].
Progressive metabolic disease (mPD) was defined as an in-
crease of at least 25 % in SUVmax for the early and late mR
assessments, or the appearance of a new FDG-avid metastatic
lesion. For both time points, a complete metabolic response
(mCR) was considered as a complete resolution of FDG up-
take within a measurable target lesion to a level less than or
equal to that of mean liver activity. A stable metabolic disease
(mSD) was between partial metabolic response (mPR) and
mPD. For the lesion-based dichotomic response analysis,
mPR or mCR lesions were classified as responding lesions
(mR), whereas mSD or mPD lesions were classified as non-
responding lesions (mNR).
Patient-based mR assessment: To describe interlesional re-
sponse heterogeneity on early PET and its evolution on late
PET response, a previously described descriptive method was
used [6]. Based on the results of the lesion-based semi-quan-
titative analysis, patients were grouped into four classes: class
I (absence of non-responding lesions), class II (mixed re-
sponse, minor proportion of tumour load is non-responding),
class III (mixed response, major proportion of tumour load is
non-responding), and class IV (all lesions showed non-re-
sponse, or presence of at least one progressive lesion, or ap-
pearance of a new lesion). Figure 2 shows examples of each
mR class.
Patient-based mR dichotomization: For response dichoto-
mization, based on the results of the primary study where
response classes have been correlated with patient outcome
parameters (OS/PFS), a patient was classified as a responder
when there was an absence of metabolically refractory lesions
[6]. Therefore, were considered as metabolic responders, all
patients showing nometabolic treatment resistant lesion (class
I) and as metabolic non-responders, all patients showing a
metabolic heterogeneous response (classes II, III, and IV).
Statistical analysis
Several reports have found a correlation between late mR and
patient outcome; therefore, late mR was considered to be a
surrogate endpoint for the current analysis [10, 20]. The hy-
pothesis of this substudy was that by using serial FDG PET-
CT, the presence and proportion of lesions resistant to treat-
ment can already be identified after one treatment cycle.
Therefore, early mR was compared to the standard “late”
mR on both a per-lesion and a per-patient basis.
To calculate the predictive values (positive predictive value
(PPV), negative predictive value (NPV)), and the concordance
rates of early mR on late mR, we constructed 2×2 contingen-
cy tables for both patient-based and lesion-based analyses.
The early and late mR were outlined in all contingency tables.
Sensitivity, specificity, PPV, and NPV were calculated with
95 % CIs based on Wilson’s method. The Kaplan–Meier
product limit method was used to describe progression-free
survival (PFS) and overall survival (OS) curves. The log-
rank test was applied to test the statistical significance of dif-






















Fig. 2 Representative examples
of each metabolic dominance
response classification. a Class I:
absence of non-responding
lesions bClass II: mixed response
with a minor proportion of non-
responding tumour load c Class
III: mixed response with a major
proportion of non-responding
tumour load dClass IV: all lesions
showed non-response, or the
presence of at least one
progressive lesion or the
appearance of a new lesion
Eur J Nucl Med Mol Imaging (2016) 43:1792–1801 1795
homogeneous response (class I) and non-responder patients
with or without a heterogeneous response (classes II, III, and
IV). To evaluate a potential selection bias for patients included
in this substudy, the difference between the survival curves of




A total of 41 patients were included in the current study. Three
patients were excluded from the mR analysis due to a lack of
target lesions identified on the baseline PET-CT for one pa-
tient and a major violation of the standardized imaging proce-
dure for two other patients. Among the seven clinical centers
participating in the primary trial, three centers systematically
performed a late mR assessment (corresponding to 35/38
(92 %) included patients), while three other centers only spo-
radically performed a late PET (corresponding to 6/37 (16 %)
included patients) and one center, which did not perform a late
PET (corresponding to 0/7 included patients).
Disease involvement was observed in the liver (n=47),
lungs (n=26), lymph nodes (n=24), bones (n=7), peritone-
um (n= 6) (carcinomatosis), large bowel (n= 3), pancreas
(n=3), rectum (n=2), sigmoid (n=2), adrenals (n=2), mus-
cle (n=1), and pleura (n=1) (Table 2).
Lesion-based early mR prediction
At the lesion-based level, a total of 124 lesions were analysed.
Early mNRwas predictive of the late mNR, with a NPVof 35/
41 (85 %) lesions. Presence of early mR was predictive of the
late mR, with a PPVof 70/83 (84%) lesions. The concordance
rates between early and late mR classes was 73 % with the
four-class classification and 85 % with the dichotomized mR
(Tables 3 and 4a).
False-negative early mR: Only 6/124 (5 %) lesions did not
respond at the early metabolic evaluation but did respond at
the late one. These six lesions were all classified as mSD in the
early evaluation and as mPR in the late one. The relative
decrease of the metabolism of 4/6 lesions was close to the
cut-off for early and late PET (delta SUVmax: −14.3, −14.2,
−14.5 and −14.7 % for early PET; delta SUVmax: −26.5,
−25.8, −25.2 and −26.3 % for late PET, respectively). The
analyses of the two remaining lesions revealed a substantial
decrease in their metabolism (delta SUVmax: −28.8 and
−27.5 %) between the early (delta SUVmax: −4.9 and
−11.2 %) and late (delta SUVmax: −33.7 and −38.7 %) met-
abolic evaluations. These two lesions were found in two dif-
ferent patients. The first lesion, located in the liver, was the
only one that responded at the late metabolic evaluation (delta
SUVmax: −33.7 %) compared to the other mNR target lesions
in this patient. The second lesion, also located in liver, showed
Table 3 Agreement on lesion-based mR between early and late PET
Metabolic response Late PET
mCR mPR mSD mPD Total
Early PET mCR 5 0 0 0 5
mPR 10 55 13 0 78
mSD 0 6 20 1 27
mPD 0 0 4 10 14
Total 15 61 37 11 124
Table 2 Sites of disease involvement and the number and frequency of
lesions involved in each site (N= 124 lesions)






Large bowel 3 2
Liver 47 38
Lungs 26 21
Lymph nodes 24 19
Bones 7 6





Table 4 Agreement between early and late PET with dichotomization
of response for lesion-based mR (A) and patient-based mR (B)
a) Lesions were considered as responding if they were classified as mCR
or mPR and as non-responding if they were classified as mSD or mPD
Late PET
R NR Total Sensitivity 0.92
R 70 13 83 Specificity 0.73
Early PET NR 6 35 41 PPV 0.84
Total 76 48 124 NPV 0.85
b) Patients were considered responders if they were classified in class I
and non-responders if they were classified in classes II, III or IV,
according to metabolic dominance response criteria
Late PET
R NR Total Sensitivity 0.93
R 13 5 18 Specificity 0.79
Early PET NR 1 19 20 PPV 0.72
Total 14 24 38 NPV 0.95
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an early mSD (delta SUVmax: −11.2 %) and a late mPR (delta
SUVmax: −38.7%), while the only other target lesion showed
an early mPR (delta SUVmax: −30.6%) and a late mCR (delta
SUVmax: −35.5 %). These two false-negative early
responding lesions showed a decrease in their metabolism at
the early PET, but the decrease was not sufficient to reach the
cut-off value, fixed at −15% of SUVmax. An illustration of this
metabolic discordant response between the early and late PET
evaluations of the second lesion is shown in Fig. 3. It is worth
noting that an increase of target lesion metabolism (>15 % of
SUVmax) at the early metabolic evaluation followed by a de-
crease at the late one (so-called “metabolic flare”) was never
observed in our study.
False-positive early mR: A total of 13/124 (10 %) lesions
did respond at the early PET but did not respond at the late
PET (Table 4a). These 13 lesions were classified as mPR for
the early and mSD for the late PET evaluation (Table 3). Two
lesions (in two patients) had a relative decrease of the lesion’s
metabolism but not reaching the cut-off value for late mR
(delta SUVmax: −24.6 % and −21.3 %). These two lesions
were located in the livers of two different patients. All other
lesions (n=11, in nine patients) did not show a significant
decrease in their metabolism on the late PET compared to
the early PET.
Patient-based early mR prediction
Interlesional response heterogeneity: The agreement on
patient-based mR between early and late PET according to
the four classes of metabolic dominance response criteria is
shown in Table 5. The overall concordance rate was 28/38
(74 %).
Evolution of response heterogeneity: All discordances be-
tween early and late classifications were observed because
patients developed non-responding (resistant) lesions between
the early and late mR evaluations. Only one patient out of 38
(3 %) evolved in the opposite way and was classified as Class
II at the early metabolic evaluation and Class I at the late one
(Table 5). This discordant patient-based response was based
on one hepatic lesion described previously that showed an
mSD (delta SUVmax: −11.2 %) at the early PET and an
mPR (delta SUVmax: −38.7 %) at the late PET, while all the
other lesions responded to treatment. Figure 3 illustrates this
example.
Dichotomized patient-based mR: The concordance rate be-
tween early and late PET was 32/38 (84 %) (Table 4b). The
metabolic non-response rate was 20/38 (53 %) at the early
PET and 24/38 (63 %) at the late PET evaluation (Table 4b).
NPV and PPV of early mR was 95 % (19/20 patients) and
72 % (13/18 patients), respectively. False-positive early mR
was found in 5/38 patients (13 %) (Table 4b). These five
patients were classified as mR (class I) on early PET but
reclassified as class II (four patients) or class IV (1 patient)
at the late metabolic evaluation. Of the four class II patients,
three developed single lesions that did not respond to therapy,
and one developed two lesions. For the remaining patient, the
analysis showed an mPD with the appearance of three new
lesions (two bone lesions and one lung lesion), clearly indi-
cating a rapid progression of the disease that was not
responding to therapy.
Prognostic value of early mR heterogeneity
Survival curves revealed a significant difference between me-
dian PFS of early mR patients with a homogeneous response
a
b
Fig. 3 Illustration of the metabolic discordant response between early
and late PET evaluations. a Patient-based discordant mR: baseline
coronal maximum intensity projection (MIP) showing two highly
metabolic right hepatic lesions (left), week 3 MIP mixed mR of hepatic
target lesions (class II) (middle), and week 6 MIP homogenous mR of all
hepatic target lesions (class I) (right). b Lesion-based discordant mR:
baseline axial PET slice showing the two highly metabolic right hepatic
lesions (left), week 3 PET mSD of the right posterior hepatic lesion and
mCR of the hepatic dome lesion (middle), and week 6 PET mPR of the
right posterior hepatic lesion (right)
Table 5 Agreement on patient-based mR between early and late PET
according to the four classes of metabolic dominance response criteria
Metabolic response Late PET
I II III IV Total
Early PET I 13 4 0 1 18
II 1 5 2 1 9
III 0 0 2 1 3
IV 0 0 0 8 8
Total 14 9 4 11 38
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(class I) and patients with at least one non-responding lesion:
5.3 months (95 % CI 2.8–10.5) versus 2.5 months (95 % CI
0.1–2.9) [P=0.003, hazard ratio (HR) 0.33 (95 % CI 0.15–
0.72)] (Fig. 4). PFS within class II, III, and IV patients seemed
similar. No significant difference was observed between me-
dian OS curves of early mR patients (class I) and mNR pa-
tients (classes II, III, and IV): 12.0 months (95 % CI 8.2–16.6)
versus 7.7 months (95 % CI 4.2–12.4) [P=0.27, hazard ratio
(HR) 0.68 (95 % CI 0.34–1.37)].
Analysis of survival curves (PFS) of early and late PET
populations
To evaluate whether a patient selection bias occurred, an anal-
ysis of survival curves and median PFS was performed for two
groups of patients: The first group was composed of patients
who had undergone an early but not a late PET (n=40), and the
second group was composed of patients who had undergone
both an early and a late PET (n=38). With this approach, the
aim was to determine whether the group to which a patient
belonged could influence his/her survival. The median PFS
was 3.0 months (95 % CI, 2.1 to 4.0 months) in the first group
of patients (early PETwithout late PET) and 3.5 months (95 %
CI, 2.6 to 5.7months) in the second group of patients (early and
late PET). No statistically significant difference was found be-
tween the median PFS of the two groups (p-value: 0.15).
Discussion
Standard metabolic response assessment using FDG PET-CT
is usually performed 8–12 weeks after therapy initiation, to-
gether with a morphology-based imaging test [10]. At that
time point, FDG PET-CT has been shown in several
haematologic and solid tumour types to be a better surrogate
for treatment outcome than conventional imaging, in both
neo-adjuvant and palliative metastatic settings [5, 21–23].
Standardized patient preparation, imaging, and response
reporting (EORTC/PERCIST) criteria have been proposed,
allowing the use of PET in multicenter trials [24]. Moreover,
as metabolic changes always precede morphological changes,
FDG PET-CT allows clinicians to detect treatment resistance
and/or response much earlier in the treatment. The tumour
shrinkage is less pronounced using targeted drugs, associated
with a cytostatic effect, consequently leading to a low sensi-
tivity of the radiological response imaging tools. An early
detection of treatment resistance is, however, needed, as it
would increase the cost-effectiveness of treatment through
better patient selection and reduce needless toxicity, related
loss of quality of life, and society costs. Another related issue
is the increasing awareness of response heterogeneity, which
should be identified early in treatment to provide a basis for
response-based treatment adaptation (e.g., by adding surgery
or locoregional therapy targeting the resistant lesion or by
changing the systemic treatment). The objective of this study
was to test FDG PET-CT in a patient cohort with
chemoresistant metastatic CRC who were treated with soraf-
enib combined with capecitabine for early detection of meta-
bolically resistant lesions/patients through correlation with
standard metabolic and morphological response assessment
(at 6–8 weeks) and patient outcome (OS/PFS). A first obser-
vation in this study was that no response fulfilling the RECIST
criteria was observed, invalidating its use as a true reference of
efficacy in the current study.
As the objective of the study was the early identification of
patients with tumour refractory to the drug combination through
Fig. 4 PFS curves estimated by
the Kaplan-Meier method
according to early homogeneous
mR (class I) versus heterogeneous
mR (classes II, II, and IV). The
difference between the median
PFS of early mR patients with a
homogeneous response (class I)
and non-responder patients with a
heterogeneous response (classes
II, III, and IV) is statistically
significant (p= 0.003)
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the characterization of interlesional metabolic response hetero-
geneity, we developed a descriptive methodology with a 4-class
response classification system defined by the presence and pro-
portion of non-responding lesions within the whole body tu-
mour load. The cut-off value for defining non-response with
the highest NPV was set to a 15 % decrease of SUVmax, based
on earlier data obtained in comparable patients treated with
polychemotherapy [15]. This cut-off is lower than the cut-offs
for response detection proposed in EORTC (25 %) and
PERCIST (30 %) that are used for standard response assess-
ment later in treatment [18, 19]. Because of this lower cut-off,
the probability of unjustified stopping of treatment should be as
low as possible. Using such a cut-off in this study, early FDG
PET-CTwas highly predictive for a metabolic non-response at a
later time-point evaluation on both a lesion basis (NPV 85 %)
and a patient basis (NPV 95 %). This demonstrates that treat-
ment resistance can already be detected as early as after one
cycle. Moreover, treatment resistance at the early PET was re-
lated to early treatment failure, as indicated by significantly
shorter PFS observed in patients with at least one non-
responding lesion in the early PET-CT (median PFS of
2.5 months versus 5.3 months in homogeneous mR patients).
A few reports exist in the literature, but only on early mR
prediction in patients with mCRC treated by classic (non-
targeted) chemotherapy. All of these studies used higher re-
sponse cut-off values primarily aimed at detecting mR and not
treatment resistance. Bender et al., in a lesion-based analysis,
demonstrated that after one cycle of 5-FU chemotherapy, a
reduction of FDG uptake occurred in therapy-sensitive metas-
tases – evaluated by morphological imaging for objective re-
sponse – and a stable or enhanced FDG uptake was indicative
of therapy resistance and/or progressive disease [25]. In con-
trast, Byström et al. did not report a significant correlation
after two cycles of chemotherapy between mR and time to
progression/OS [26]. Several methodological limitations of
that study were reported [27]. First, there were no data regard-
ing the histopathological subgroups and related baseline FDG
avidity of the mCRC patients [28]. Second, the size of lesions
was not indicated. It is known that in small lesions, the quan-
titative characterization of tumour metabolism with FDG
PET-CT involves the partial volume effect as one of the main
sources of error [29]. In the current study, target lesions were
defined on the baseline FDG PET-CT according to strict
criteria: FDG avidity (higher than two times the normal
liver/thoracic aorta uptake) and size (more than 15 mm).
More recently, some studies showed that an FDG PET-CT
evaluation after a single course of chemotherapy is able to
discriminate, with a high NPV, patients unlikely to benefit
from the treatment in terms of both tumoural shrinkage and
general outcome (PFS/OS) [9, 10, 12].
This study did not observe any signs of a “metabolic flare
phenomenon”, previously described in a report by Findlay
et al. as a transient metabolic pseudo-progression at 1–2 weeks
after the start of chemotherapy in ultimately responding le-
sions [30]. Such a false-positive non-response early metabolic
response during chemotherapy has not been confirmed by
later studies. Sources of error in the report by Findlay et al.
were the lack of imaging standardization and of patient prep-
aration at that time (e.g., timing between injection and start of
PET acquisition ranged from 45 to 99 min; in our study this
time lag was fixed at a maximum of 15 min) [30]. The flare
phenomenon, in the context of chemotherapy and molecular
targeted therapy, seems, therefore, to be more a misinterpreta-
tion due to all types of biases than a real biological phenom-
enon that could be observed in humans with in vivo metabolic
imaging [31]. Indeed, only small animal PET studies have
reported this phenomenon after chemotherapy; i.e., early
(D1-7) transient increase in FDG accumulation due to an in-
flammatory infiltrate that consists of neutrophils, lympho-
cytes, and macrophages at the treatment site [32]. A transient
early metabolic flare in lesions that ultimately will respond to
treatment has been well described in tumours following radio-
therapy (due to inflammation) and hormonal therapy (due to a
partial agonistic effect) [33–35]. It is expected that new cancer
immunotherapies using antibodies, vaccines, and cell-based
therapies will probably demonstrate a metabolic flare, thereby
impairing the future use of FDG as a tracer for early detection
of treatment resistance [36].
In this study, only 1/38 (3 %) patients and 6/124 (5 %)
lesions were falsely considered as non-responding on early
PET. All of these six early mNR lesions were classified as
mSD on the early PET. In four of these six lesions, the false-
negative mR was based on the threshold effect (15 % for early
vs 25 % for late PET). For the remaining two lesions, no
plausible explanation of the postponed metabolic responses
was found. These six early mNR lesions had a minor impact
on the patient-based response classification. Indeed, a change
of patient-based classification occurred in only one patient (a
shift from class II at early mR to a class I at late mR).
This study particularly looked at interlesional tumour re-
sponse heterogeneity and its evolution during treatment. It
was found that in all but one patient, tumour heterogeneity
persisted during treatment and that in patients with early
heterogeneous responses, the number of treatment-resistant
lesions increased with time. These results reflect that treat-
ment resistance persists with time or can evolve in a more
aggressive disease [37]. The latter observation underscores
the negative impact of response heterogeneity on patient
outcome, which was also confirmed by the PFS analysis that
showed a significant drop in PFS in the presence of at least
one resistant lesion (median PFS of 2.5 months versus
5.3 months in homogeneous mR patients). In an earlier re-
port on early FDG PET response assessment in mCRC using
polychemotherapy without targeted treatment, a similar drop
in PFS was described when the major part of the tumour
load was non-responding [6]. In this study, performed with a
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larger patient cohort and a more potent therapy, it could be
shown that even patients with a minor non-responding tu-
mour load on early PET did have impaired prognosis. An
ongoing trial using a treatment from the same family as
sorafenib (regorafenib) is currently seeking confirmation of
these results [8, 38]. That, if granted, will generate subse-
quent prospective trials assessing the value of early PET to
guide treatment adaptation based on the presence and pro-
portion of non-responsive lesions with the aim to impact
positively the patient care and health economics.
Limitations of this study
A potential limitation of the study is that the standard “late”
PET was only performed in a subset of patients (n=38) par-
ticipating in the main trial, which included 94 patients.
However, all patients included in the substudy systematically
underwent the late PET. To formally exclude a bias through
preferential selection of patients for the late PET assessment
who were responding to treatment, a comparison of survival
(PFS) of the two groups of patients (early versus early and late
PET) was performed and did not reveal a significant differ-
ence of median PFS between the two groups. As shown in the
results section, three centers did not systematically perform a
late PET. Only five patients in these centers were included in
the late metabolic analysis. These five patients represent 13 %
(five out of 38) of all patients included in the late PETanalysis.
If there was a selection of center bias, it was very limited.
Conclusion
Early metabolic response assessment using FDG PET-CT
after one cycle of a combined sorafenib-capecitabine in pa-
tients with chemorefractory mCRC allows, with a high ac-
curacy, the early identification of lesions resistant to treat-
ment. Due to the absence of the so-called “metabolic flare
phenomenon” and the very low false-negative rate of pa-
tient/lesion, a later time point metabolic response evaluation
is not necessary if the early metabolic response assessment
has demonstrated treatment resistance.
Acknowledgments The authors express their deep gratitude to the pa-
tients who agreed to participate in this project and to their families.
This academic work was supported and sponsored by the Jules Bordet
Institute. The main study was financed by a research grant from Bayer.
The results were presented at the EANM’14 - Annual Congress of the
European Association of Nuclear Medicine as a poster presentation dur-
ing the general poster session (abstract 2087).
Compliance with ethical standards
Conflict of interest statement Bayer Healthcare AG has provided so-
rafenib but played no further role. AH played an advisory role and re-
ceived honoraria from Sirtex, Roche, Bayer, Sanofi and Amgen; PF
played an advisory role and received honoraria from Sirtex, Roche, and
Bayer; CG played a consultant/advisory role from GE healthcare, Algeta
ASA, and received academic support from Servier, Synta
Pharmaceuticals, and Genzyme. The author and all other coauthors have
no conflicts of interest to disclose.
Ethical approval All procedures performed in studies involving hu-
man participants were in accordance with the ethical standards of the
institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
This article does not contain any studies with animals performed by
any of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S,Mathers C, RebeloM,
et al. Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:
359–86.
2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou
M, et al. Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): an international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:
303–12.
3. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A,
Büchert M, et al. Regorafenib (BAY 73–4506) in advanced colo-
rectal cancer: a phase I study. Br J Cancer. 2012;106:1722–7.
4. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U,
et al. A phase I dose–escalation study of regorafenib (BAY 73–
4506), an inhibitor of oncogenic, angiogenic, and stromal kinases,
in patients with advanced solid tumors. Clin Cancer Res. 2012;18:
2658–67.
5. Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a
new paradigm for imaging. Oncologist. 2008;13:8–13.
6. Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P,
Ameye L, et al. Serial FDG–PET/CT for early outcome prediction
in patients with metastatic colorectal cancer undergoing chemother-
apy. Ann Oncol. 2012;23:1687–93.
7. de Geus-Oei LF, van Laarhoven HWM, Visser EP, Hermsen R, van
Hoorn BA, Kamm YJL, et al. Chemotherapy response evaluation
with FDG-PET in patients with colorectal cancer. Ann Oncol.
2008;19:348–52.
8. Hendlisz A, Deleporte A, Vandeputte C, Charette N, Paesmans M,
Guiot T, et al. Regorafenib assessment in refractory advanced co-
lorectal cancer: RegARd-C study protocol. BMJ Open. 2015;5,
e007189.
9. Engelmann BE, Loft A, Kjaer A, Nielsen HJ, Gerds TA, von
Benzon E, et al. Positron emission tomography/computed tomog-
raphy and biomarkers for early treatment response evaluation in
metastatic colon cancer. Oncologist. 2014;19:164–72.
10. Liu FY, Yen TC, Wang JY, Yang TS. Early prediction by 18F-FDG
PET/CT for progression-free survival and overall survival in pa-
tients with metastatic colorectal cancer receiving third-line
cetuximab-based therapy. Clin Nucl Med. 2015;40:200–5.
1800 Eur J Nucl Med Mol Imaging (2016) 43:1792–1801
11. Desar IME, van Herpen CML, van Laarhoven HWM, Barentsz JO,
Oyen WJG, van der Graaf WTA. Beyond RECIST: molecular and
functional imaging techniques for evaluation of response to targeted
therapy. Cancer Treat Rev. 2009;35:309–21.
12. Vriens D, de Geus LF. Tailoring therapy in colorectal cancer by
PET-CT. Q J Nucl Med Mol Imaging. 2009;53:224–44.
13. Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV,
Høgdall EVS, et al. CT versus FDG‐PET/CT response evaluation in
patients with metastatic colorectal cancer treated with irinotecan
and cetuximab. Cancer Med. 2014;3:1294–301.
14. Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M,
Holbrechts S, et al. The prognostic significance of metabolic re-
sponse heterogeneity in metastatic colorectal cancer. PLoS One.
2015;10, e0138341.
15. Buvat I, Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P,
et al. Lesion-based detection of early chemosensitivity using serial
static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med
Mol Imaging. 2012;39:1628–34.
16. Deleporte A, Hendlisz A, Garcia C, Delaunoit T. SoMore trial: early
metabolic response assessment of a sorafenib (SOR) and capecita-
bine (CAP) combination in chemorefractory metastatic colorectal
cancer (mCRC). J Clin Oncol. 2014;32 Suppl 3.
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE,
McFadden ET, et al. Toxicity and response criteria of the eastern
cooperative oncology group. Am J Clin Oncol. 1982;5:649.
18. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to
PERCIST: evolving considerations for PET response criteria in sol-
id tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.
19. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O,
Lammertsma AA, et al. Measurement of clinical and subclinical
tumour response using [18F]-fluorodeoxyglucose and positron
emission tomography: review and 1999 EORTC recommenda-
tions. Eur J Cancer. 1999;35:1773–82.
20. Dimitrakopoulou A. Prognostic aspects of 18F-FDG PET kinetics
in patients withmetastatic colorectal carcinoma receiving FOLFOX
chemotherapy. J Nucl Med. 2004;45:1480–7.
21. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M,
Hutchings M, Mueller SP, et al. Role of imaging in the staging
and response assessment of lymphoma: consensus of the interna-
tional conference on malignant lymphomas imaging working
group. J Clin Oncol. 2014;32:3048–58.
22. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH,
Zucca E, et al. Recommendations for initial evaluation, staging,
and response assessment of Hodgkin and Non-Hodgkin lymphoma:
the lugano classification. J Clin Oncol. 2014;32:3059–67.
23. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P,
Nuyts J, et al. 18FDG-positron emission tomography for the early
prediction of response in advanced soft tissue sarcoma treated with
imatinib mesylate (Glivec®). Eur J Cancer. 2003;39:2012–20.
24. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch
K, EschnerW, et al. FDGPET/CT: EANMprocedure guidelines for
tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging.
2014;42:328–54.
25. Bender H, Bangard N, Metten N, Bangard M, Mezger J,
Schomburg A, et al. Possible role of FDG-PET in the early predic-
tion of therapy outcome in liver metastases of colorectal cancer.
Hybridoma. 1999;18:87–91.
26. Bystrom P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren
P, et al. Early prediction of response to first-line chemotherapy by
sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission to-
mography in patients with advanced colorectal cancer. Ann Oncol.
2009;20:1057–61.
27. Arslan C, Kilickap S. FDG-PET: for early prediction of response to
the first-line chemotherapy in metastatic colorectal cancer? Ann
Oncol. 2009;20:1149–50.
28. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti
F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment
of suspected metastatic or recurrent adenocarcinoma of the colon
and rectum. Dis Colon Rectum. 2000;43:759–70.
29. Maisonobe J, Garcia CA, Necib H, Vanderlinden B, Hendlisz A,
Flamen P, et al. Comparison of PET metabolic indices for the early
assessment of tumour response in metastatic colorectal cancer pa-
tients treated by polychemotherapy. Eur J Nucl Med Mol Imaging.
2013;40:166–74.
30. Findlay M, Young H, Cunningham D. Noninvasive monitoring of
tumor metabolism using fluorodeoxyglucose and positron emission
tomography in colorectal cancer liver metastases: correlation with
tumor response to fluorouracil. J Clin Oncol. 1996;14:700–8.
31. Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18 F-
Fluoride Ion PET bone scanning. Am J Roentgenol. 2006;186:
1783–6.
32. Aliaga A, Rousseau JA, Cadorette J, Croteau É. A small animal
positron emission tomography study of the effect of chemotherapy
and hormonal therapy on the uptake of 2-deoxy-2-[F-18] fluoro-D-
glucose in murine models of breast cancer. Mol Imaging Biol.
2007;9:144–50.
33. Weber WA. Use of PET for monitoring cancer therapy and for
predicting outcome. J Nucl Med. 2005;6:983–95.
34. Basu S, Nair N. Is it time to incorporate quantitative functional
imaging data, FDG PET in particular, into the response evaluation
criteria in solid tumours? Nucl Med Commun. 2006;27:413–6.
35. Basu S, Alavi A. Defining co-related parameters between ‘metabol-
ic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and
establishing guidelines for assessing response to treatment in can-
cer. Eur J Nucl Med Mol Imaging. 2007;34:441–3.
36. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C,
et al. Guidelines for the evaluation of immune therapy activity in
solid tumors: immune-related response criteria. Clin Cancer Res.
2009;15:7412–20.
37. Troiani T, Martinelli E, Napolitano S, Morgillo F, Belli G, Cioffi L,
et al. Molecular aspects of resistance to biological and Non-
biological drugs and strategies to overcome resistance in colorectal
cancer. Curr Med Chem. 2014;21(14):1639–53.
38. Hudson HM, Larkin RS. Accelerated image reconstruction using
ordered subsets of projection data. IEEE Trans Med Imaging.
1994;13:601–9.
Eur J Nucl Med Mol Imaging (2016) 43:1792–1801 1801
